INS and Insulin resistance: In this way, it is difficult to assume a general standardized suggestion regarding the initial insulin dose in IRD cases since the patient’s insulin-resistance degree (i.e., presence of interferences of insulin action on target cells) and residual beta-cell secretory capacity are unknown.